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Abstract
Background
The effect of antiretroviral treatment (ART) eligibility expansions on patient outcomes,
including rates of timely ART initiation among those enrolling in care, has not been assessed
on a large scale. In addition, it is not known whether ART eligibility expansions may lead to
“crowding out” of sicker patients.
Methods and findings
We examined changes in timely ART initiation (within 6 months) at the original site of HIV
care enrollment after ART eligibility expansions among 284,740 adult ART-naïve patients at
171 International Epidemiology Databases to Evaluate AIDS (IeDEA) network sites in 22
countries where national policies expanding ART eligibility were introduced between 2007
and 2015. Half of the sites included in this analysis were from Southern Africa, one-third were
from East Africa, and the remainder were from the Asia-Pacific, Central Africa, North Amer-
ica, and South and Central America regions. The median age of patients enrolling in care at
contributing sites was 33.5 years, and the median percentage of female patients at these
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002534 March 23, 2018 1 / 19
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Tymejczyk O, Brazier E, Yiannoutsos C,
Wools-Kaloustian K, Althoff K, Crabtree-Ramı´rez B,
et al. (2018) HIV treatment eligibility expansion and
timely antiretroviral treatment initiation following
enrollment in HIV care: A metaregression analysis
of programmatic data from 22 countries. PLoS
Med 15(3): e1002534. https://doi.org/10.1371/
journal.pmed.1002534
Academic Editor: Marie-Louise Newell, University
of Southampton, UNITED KINGDOM
Received: August 30, 2017
Accepted: February 14, 2018
Published: March 23, 2018
Copyright: © 2018 Tymejczyk et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Complete data for
this study cannot be posted in a supplemental file
or a public repository because of legal and ethical
restrictions. The Principles of Collaboration under
which the IeDEA multiregional collaboration was
founded and the regulatory requirements of the
different countries’ IRBs require the submission
and approval of a project concept sheet by the
IeDEA Executive Committee and the principal
investigators from participating regions. All
clinics was 62.5%. We assessed the 6-month cumulative incidence of timely ART initiation
(CI-ART) before and after major expansions of ART eligibility (i.e., expansion to treat persons
with CD4 350 cells/μL [145 sites in 22 countries] and CD4 500 cells/μL [152 sites in 15
countries]). Random effects metaregression models were used to estimate absolute changes
in CI-ART at each site before and after guideline expansion. The crude pooled estimate of
change in CI-ART was 4.3 percentage points (95% confidence interval [CI] 2.6 to 6.1) after
ART eligibility expansion to CD4 350, from a baseline median CI-ART of 53%; and 15.9
percentage points (pp) (95% CI 14.3 to 17.4) after ART eligibility expansion to CD4 500,
from a baseline median CI-ART of 57%. The largest increases in CI-ART were observed
among those newly eligible for treatment (18.2 pp after expansion to CD4 350 and 47.4 pp
after expansion to CD4 500), with no change or small increases among those eligible
under prior guidelines (CD4 350: −0.6 pp, 95% CI −2.0 to 0.7 pp; CD4 500: 4.9 pp, 95%
CI 3.3 to 6.5 pp). For ART eligibility expansion to CD4 500, changes in CI-ART were largest
among younger patients (16–24 years: 21.5 pp, 95% CI 18.9 to 24.2 pp). Key limitations
include the lack of a counterfactual and difficulty accounting for secular outcome trends, due
to universal exposure to guideline changes in each country.
Conclusions
These findings underscore the potential of ART eligibility expansion to improve the timeli-
ness of ART initiation globally, particularly for young adults.
Author summary
Why was this study done?
• In 2009 and 2013, the World Health Organization (WHO) recommended that HIV
patients with CD4 counts350 and500 cells/μL, respectively, initiate antiretroviral
treatment (ART).
• The expansion of ART eligibility criteria has the potential to increase ART initiation
rates, especially among healthier patients; however, it could also lead to “crowding out”
of persons with more advanced disease and lower rates of ART initiation among these
patients.
• While many countries have adopted WHO guidelines, the impact of ART eligibility
expansions on timely ART initiation has not been studied on a large scale.
What did the researchers do and find?
• We examined the changes in timely ART initiation after national ART eligibility criteria
were expanded to CD4 350 and/or CD4 500 in 22 countries, using data on 284,740
adult ART-naïve patients at 171 sites in the International Epidemiology Databases to
Evaluate AIDS (IeDEA) network.
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datasets provided by IeDEA are deidentified
according to HIPAA Safe Harbor guidelines, with
the exception of dates in some of the regions.
Disclosure of a person’s HIV status can be highly
stigmatizing, and since reidentification of
deidentified datasets may be possible when they
are combined with publicly available datasets (see
work of Dr. Latanya Sweeney), IeDEA promotes the
signing of a Data Use Agreement before HIV
clinical data can be released. To request data,
readers may contact IeDEA for consideration and
instructions by filling out the online form available
at www.iedea.org/home/who-we-are and
completing the application at www.iedea.org/wp-
content/uploads/2017/05/IeDEA_Multiregional_
Concept_Application_Form_August_2016.docx.
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• Site-level cumulative incidence of ART initiation (CI-ART) within 6 months of enroll-
ment increased by 4.3 percentage points after national ART eligibility expansion to CD4
 350 and by 15.9 percentage points after expansion to CD4 500.
• At the individual level, increases were greatest among patients 16–24 years old at enroll-
ment and those newly eligible for ART. No change or small improvements in CI-ART
were also observed among patients already eligible for ART before eligibility expansion.
• At the site level, sites with the lowest initial levels of CI-ART experienced the greatest
increases following guideline expansions.
What do these findings mean?
• Overall, ART eligibility expansions were followed by appreciable improvements in
timely ART initiation.
• Many clinics can support ART initiation among newly eligible patients with less
advanced disease without negatively affecting ART initiation rates among those with
more advanced disease.
• These findings illustrate the potential of ART eligibility expansion to improve the timeli-
ness of ART initiation and patient outcomes along the care cascade globally, particularly
for younger adults, in support of the Joint United Nations Programme on HIV/AIDS
(UNAIDS) 90-90-90 targets, thereby reducing morbidity, mortality, and onward HIV
transmission.
Introduction
Individual and population-level benefits of antiretroviral treatment (ART) are maximized
when treatment is initiated soon after HIV infection occurs [1–5]. ART slows the progression
of HIV to AIDS and reduces infections and mortality among those living with HIV [6,7]. In
addition, ART lowers viral load in HIV-infected individuals, thereby reducing the risk of on-
ward HIV transmission [2,7–11]. Recent studies have shown that immediate versus delayed
initiation of ART reduces risks of AIDS and severe opportunistic illnesses [12]. Some studies
suggest that earlier initiation of ART may also improve rates of retention in care and medica-
tion adherence, and promote more rapid achievement of viral load suppression [13–15]. As a
result of this evidence, the World Health Organization (WHO) now recommends immediate
initiation of ART for all people diagnosed with HIV, regardless of CD4 count [16].
A systematic review of retention in HIV care between testing and treatment among patients
who were ineligible to initiate ART at the time of diagnosis estimated that less than one-third
of patients remained continuously engaged in HIV care until the point of ART eligibility [17].
Other reviews of losses along the HIV care continuum in sub-Saharan Africa have estimated
that 54%–69% of those ineligible for ART at the time of HIV care enrollment are lost to care
prior to ART initiation, with the poorest retention rates among adolescents, young adults, and
those enrolling in care at earlier stages of infection [18,19]. In contrast, among patients eligible
for ART at the time of enrollment into care, the proportions lost to care prior to ART initiation
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were 25%–36% [18,19]. In a recent analysis from South Africa, which compared outcomes
among patients just below and just above the ART eligibility cutoff, patient eligibility for im-
mediate treatment was associated with a 25 percentage point (pp) increase in ART initiation
and an 18 pp increase in 12-month retention [20].
Using longitudinal data on patients enrolling in HIV care from the International Epidemi-
ology Databases to Evaluate AIDS (IeDEA) network, we sought to assess changes in timely
ART initiation at the original site of care enrollment following major expansions in HIV treat-
ment guidelines across multiple countries and regions and to identify factors associated with
these changes.
Methods
Data sources and management
Patient data. IeDEA (www.iedea.org) contains sociodemographic and clinical data for
over 1.7 million patients enrolled in HIV care in 46 countries across 7 regional cohort collabora-
tions [21]. The vast majority (87%) of IeDEA sites are public sector health facilities, including
both primary-level sites (42%) and secondary/tertiary-level sites (58%) [22], thus representing a
diverse population of HIV patients. Almost all IeDEA sites offer HIV counseling and testing
on-site, and common entry points into HIV care at these sites are internal referrals from other
units (i.e., HIV counseling and testing), antenatal care, outpatient departments, and referrals
from other health facilities, as well as community-based testing programs in their catchment
areas [22,23]. In this analysis, we used prospectively and retrospectively collected data from
2006–2017 for 6 regional cohorts with pre-ART data available (Asia-Pacific, Central and South
America, Central Africa, East Africa, North America, and Southern Africa). Prior to data merge
and analysis, each region’s data were harmonized by regional data managers in accordance with
IeDEA data exchange standards regarding variable definitions, data cleaning, and formatting.
ART guidelines
We conducted a systematic search for current and historical ART eligibility guidelines of coun-
tries participating in IeDEA, including sources such as the Joint United Nations Programme on
HIV/AIDS (UNAIDS) Database of National HIV Guidelines [24], the International Association
of Providers of AIDS Care (IAPAC) Global HIV Watch [25], the HIV Treatment Guideline
Database, health ministry websites, search engines, and published literature, including ART
guideline reviews [26–28]. For countries with no publicly available ART guidelines, we obtained
information from in-country HIV clinicians, researchers, and ministry of health officials. We
identified the time points when each country expanded ART eligibility to include asymptomatic
people living with HIV (PLWH) with CD4 counts350 cells/μL and500 cells/μL. We also
identified concurrent expansions of guidelines related to expanded treatment for pregnant
women and patients coinfected with tuberculosis, regardless of other eligibility criteria (i.e.,
CD4 counts or clinical staging). If the exact month of ART eligibility expansion was unknown,
a midyear value was used.
This cohort study utilized deidentified data approved for use by local ethical committees in
each of the IeDEA regions included in the analysis.
Eligibility criteria
Sites eligible for inclusion had to have HIV care data available on patients for the period after
care enrollment but preceding ART initiation (pre-ART data), as well as data on both ART ini-
tiators and noninitiators. Patients had to be at least 16 years old at enrollment (18 in North
ART eligibility expansion and timely ART initiation
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America) and have at least 12 months of possible follow-up between enrollment and database
closure. Patients were excluded if they transferred to an IeDEA site from another clinic, lacked
a clinic visit and lab record, or were known not to be ART naïve at enrollment (with ART
defined as any regimen of at least 3 antiretroviral drugs, excluding treatment taken for preven-
tion of maternal-to-child transmission).
To ensure that there was no differential selection into the sample by ART eligibility, distri-
butions of CD4 counts at enrollment were assessed with respect to possible discontinuities at
the point of ART eligibility (CD4 = 350 and CD4 = 500 for the 2 analyses), which would indi-
cate potential exclusion of non-ART-eligible patients from contributing sites’ cohorts (S1
Text).
Outcome
The outcome of interest was site-level absolute pp change in cumulative incidence of ART ini-
tiation (CI-ART) within 6 months of enrollment at each site—namely, the difference in
CI-ART between those enrolling in HIV care 6–18 months prior to national ART eligibility
expansion (“pre” or baseline period) and those enrolling 6–18 months thereafter (“post”
period). Pp changes were computed separately for ART eligibility expansions to CD4 counts
350 cells/μL and500 cells/μL. Patients enrolling in the 6 months immediately preceding
and following guideline introduction were excluded to allow for early or lagged implementa-
tion of national guidelines at the site level and to ensure that the 6-month CI-ART outcome
for the “pre” period occurred before the guideline change. Additionally, to ensure sufficient
data for reliable outcome estimation, sites that had fewer than 30 study eligible patients who
enrolled in either of the “pre” and “post” periods bracketing ART eligibility expansion were
excluded.
To derive the outcome measure, we estimated overall 6-month CI-ART separately for the
“pre” and “post” ART eligibility expansion periods via competing risks regression with the
Aalen-Johansen estimator, treating death and pre-ART loss to clinic as competing events. To
minimize the risk of misclassifying temporarily disengaged patients as lost, pre-ART loss to
clinic was defined as not returning to clinic for at least 12 months, with no evidence of subse-
quent return.
Statistical and analytic methods
The CI-ART was estimated via competing risk methods, with the Aalen-Johansen estimator,
and treating death and loss to clinic as competing risks, as outlined in a July 2016 concept pro-
posal to the IeDEA Executive Committee (S2 Text), which also prespecified inclusion and
exclusion criteria, outcome definitions, and key stratification variables. As discussed in the
appendix (S2 Text), other analytic approaches, including the use of site-level metaregression
and the pre-post within-site comparisons to derive the outcome, were selected after data
became available.
To assess variability of change in 6-month CI-ART across sites, forest plots were used to
visualize site-level outcomes, and between-site variances (tau-squared) and p-values from
chi-squared tests of between-site heterogeneity were calculated.
Pooled estimates and stratification
We calculated pooled summary estimates of the pp change in 6-month CI-ART across all sites
for each major expansion in treatment eligibility criteria, along with corresponding 95% confi-
dence intervals (CIs). We stratified all estimates across several site and patient characteristics.
Site characteristics included IeDEA region (see “Data Sources”), site setting (urban versus
ART eligibility expansion and timely ART initiation
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rural), and site-level summary measures of the patient population enrolling at the site, includ-
ing overall proportion of female clients (45%, 45%–65%, >65%); baseline 6-month CI-ART
(grouped in quartiles) among all patients and among those previously eligible for treatment as
a site-level measure of the preexisting service level and capacity to expand; and proportion of
patients eligible for treatment in the “post” period, under expanded guidelines, as a measure of
unmet need for treatment. Patient characteristics included sex, age at enrollment (dichoto-
mized into 16–24 years and25 years, to align with the 15–24 age category that is commonly
used by WHO [29]), and CD4 count at enrollment. CD4 count at enrollment was categorized
to reflect patients’ ART eligibility status vis-à-vis each guideline change: newly eligible (CD4
count 201–350) and previously eligible (CD4 200) for the ART eligibility expansion to
CD4 350 cells/μL and newly eligible (CD4 351–500) and previously eligible (CD4 350), in
analyses of ART eligibility expansion to CD4 500 cells/μL.
Metaregression models
Linear random effects metaregression models were used to examine factors associated with
changes in 6-month CI-ART while controlling for concurrent expansions of other ART eligi-
bility criteria and to assess the predicted magnitude of change in 6-month CI-ART following
ART eligibility expansions. Bivariate and multivariable associations between the pp change in
6-month CI-ART and site and patient population characteristics were examined through lin-
ear random effects metaregression, adjusted for concurrent expansions of ART eligibility crite-
ria for pregnant women and tuberculosis patients. To meet the assumption of linearity in the
association between continuous independent variables and the outcome, cohort size was log
transformed.
Covariates used in metaregression models included variables related to site characteristics
(i.e., baseline 6-month CI-ART, baseline median enrollment CD4, median age at enrollment,
and proportion of female patients at a site), as well as binary variables related to concurrent
guideline changes extending HIV treatment to all pregnant women and tuberculosis patients.
Site-level covariates were derived separately for each of the 2 ART eligibility expansions (to
CD4 350 cells/μL and to CD4 500 cells/μL), based on each site’s patient population in the
periods bracketing each ART eligibility expansion.
Analyses were completed in Stata 14.
Results
Overall, 260 IeDEA sites had provided longitudinal data on at least 60 patients–the minimum
for potential inclusion in the analysis. Thirty sites were further excluded because of lack of
data on pre-ART patients. Among the remaining 230 sites, 225 were in countries where eligi-
bility expansions of interest occurred during the period under study. Among these sites, 171
had sufficiently large cohorts for inclusion in this analysis (i.e., at least 30 patients meeting the
eligibility criteria described above in each 12-month period bracketing guideline expansion).
ART eligibility expansions and site characteristics
The analysis of ART eligibility expansion to treat asymptomatic PLWH with CD4 count350
cells/μL included 145 sites (with 169,717 patients) in 22 countries where guidelines changed
between 2007 and 2012. Six of these countries revised national treatment eligibility guidelines
before WHO’s November 2009 recommendation [30] to initiate treatment at CD4 350, by a
mean of 15 months (range 5–27 months). Among the 16 countries that adopted expanded
guidelines after WHO’s recommendation, the mean time elapsed was 20 months (range 6–31
months).
ART eligibility expansion and timely ART initiation
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The analysis of ART eligibility expansion for asymptomatic PLWH with CD4 count500
cells/μL included 152 sites (with 128,552 patients) in 15 countries where guidelines changed
between 2009 and 2015. Three of these countries introduced new guidelines prior to WHO’s
June 2013 recommendation [31] on treatment eligibility (mean of 28 months; range 11–42
months). Among the remaining 12 countries, national guideline change followed WHO rec-
ommendations by a mean of 9 months (range 1–24 months).
For both analyses, half of the sites were from Southern Africa (50% and 51%, respectively;
Table 1).
During the periods preceding ART eligibility expansions to CD4 350 and CD4 500,
the median proportion of patients initiating ART within 6 months of enrollment was 53.3%
and 57.5% of patients, respectively (Table 2).
Patient demographics were similar across sites, with a median age of 34 years and female
patients comprising more than 60% of patients on average. Baseline median CD4 counts at
enrollment into HIV care were higher among sites included in the analysis of CD4500 ART
eligibility expansion than among the CD4350 ART eligibility expansion sites (273 cells/μL
versus 223 cells/μL). However, a larger proportion of patients were missing data for CD4
count at enrollment during both the “pre” and “post” periods in the analysis of the second
ART eligibility expansion (median 33% versus 14% and 39% versus 20%, respectively;
Table 1).
Pooled estimates of change in 6-month CI-ART following ART eligibility
expansions
Marked changes in CI-ART were observed after each expansion in treatment eligibility: 4.3 pp
(95% CI 2.6–6.1 pp) after the expansion to CD4 350 cells/μL and 15.9 pp (95% CI 14.3–17.4 pp)
after the expansion to CD4 500 cells/μL (Table 2). There was considerable heterogeneity in site-
level changes in CI-ART for both guideline expansions, and heterogeneity chi-squared tests were
statistically significant (both p<0.001). However, a much larger proportion of sites experienced
positive changes in 6-month CI-ART following the latter ART eligibility expansion to CD4 500
cells/μL (Fig 1A and 1B). Overall, 33% of sites (48/145) had statistically significant increases in
6-month CI-ART after the expansion to CD4 350 cells/μL, 57% of sites (83/145) had no statisti-
cally discernible change, and 10% (14/145) had statistically significant decreases. After expansion
to CD4 500 cells/μL, 74% of sites (112/152) had statistically significant increases, 26% of sites
(39/152) had no statistically discernible change, and<1% (1/152) had a statistically significant
decrease.
In stratified analyses of the guideline expansion to treat patients with CD4 350 cells/μL,
changes in 6-month CI-ART were most pronounced at sites in Asia-Pacific, East Africa, and
Central Africa (12.0, 7.6 and 7.3 pp, respectively), at sites with higher proportions of newly eli-
gible patients in the “post” period (4.9 pp and 7.9 pp for clinics in the top 2 quartiles of the pro-
portion of patients newly eligible for treatment, respectively), and sites in the lowest quartile of
“pre” period 6-month CI-ART (11.8 pp). There was also a trend in the association between
lower “pre” period 6-month CI-ART among previously eligible patients specifically and greater
site-level change in CI-ART after guideline expansion (Table 2).
Following the CD4 500 expansion, the largest changes in CI-ART were observed in South-
ern and East Africa (17.6 pp and 15.8 pp, respectively). As observed in the CD4 350 analysis,
there was a trend of greater change in 6-month CI-ART with lower “pre” period 6-month
CI-ART (overall and among previously eligible patients specifically); sites in the lowest quartile of
“pre” period 6-month CI-ART had the largest changes in CI-ART following ART eligibility
expansion (26.2 pp). However, in contrast to trends observed following expansion to CD4 350,
ART eligibility expansion and timely ART initiation
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there was no trend in CI-ART across quartiles of proportion of newly eligible patients in the
“post” period (Table 2).
In analyses stratified by patient characteristics, no significant differences in the pp change
in CI-ART were observed by sex or age after expansion to CD4 350 cells/μL. However, after
Table 1. Characteristics of 171 sites and 284,740 patients included in the analyses.
Guideline expansion to
CD4 350
Guideline expansion to
CD4 500
Sitesa included in
both analyses
Overall Sites Patients Sites Patients
N countries N
sites
N% N % N% N % N (%)
Overall 22 171 145 100% 169,717 100% 152 100% 128,552 100% 126/171 (74%)
Region
Asia-Pacific Cambodia, Hong Kong, India,
Indonesia, and Vietnam
6 6 4% 2,868 2% 2 1% 378 <1% 2/6 (33%)
Central Africa Burundi, DRC, and Rwanda 14 12 8% 5,886 3% 13 9% 3,559 3% 11/14 (79%)
East Africa Kenya, Tanzania, Uganda 50 36 25% 42,804 25% 46 30% 36,856 29% 32/50 (64%)
North America Canada and United States 13 13 9% 7,262 4% 10 7% 6,949 5% 10/13 (77%)
Southern Africa Malawi, South Africa, Zambia,
and Zimbabwe
83 73 50% 109,012 64% 78 51% 79,664 62% 68/83 (82%)
South and Central America Argentina, Brazil, Chile, Mexico,
and Peru
5 5 3% 1,885 1% 3 2% 1,146 1% 3/5 (60%)
Site setting
Urban 75 72 50% 81,077 48% 65 43% 60,410 47% 62/75 (83%)
Rural 57 42 29% 61,200 36% 52 34% 45,690 36% 37/57 (65%)
Unknown 39 31 21% 27,440 16% 35 23% 22,452 17% 27/39 (69%)
Overall cohort characteristics (“pre” and “post” groups)
Median age at enrollment (IQR) 34 (32–
35)
33 (32–
35)
Median % women in cohort (IQR) 62 (60–
66)
63 (59–
66)
Cohort characteristics at baseline (“pre” group)
Median % with CD4 at enrollment
(IQR)
86 (77–
92)
67 (53–
80)
Median CD4 at enrollment (IQR) 223 (198–
290)
273 (243–
331)
Median % newly ART eligible under
expanded guidelines (IQR)b,c
19 (16–
23)
12 (8–15)
Cohort characteristics after expansion (“post” group)
Median % with CD4 at enrollment
(IQR)
80 (64–
88)
61 (37–
79)
Median CD4 at enrollment
(IQR)
261 (230–
296)
284 (248–
344)
Median % newly ART eligible under
expanded guidelines (IQR)b,c
19 (15–
21)
11 (8–15)
Abbreviations: ART, antiretroviral treatment; DRC, Democratic Republic of the Congo.
a There were 13,529 patients included in both analyses (in the “post” period of the expansion to CD4 350 analysis and the “pre” period in the expansion to CD4500
analysis)
b Those with unknown eligibility were included in the denominator
c Defined as patients with an enrollment CD4 count between 201 and350 (in the expansion to CD4 350 analysis) or 351 and500 (in the expansion to CD4 500
analysis).
https://doi.org/10.1371/journal.pmed.1002534.t001
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Table 2. Overall and pooled change in 6-month cumulative incidence of antiretroviral treatment initiation (CI-ART) after ART eligibility guideline expansion to
CD4 350 and CD4 500.
Guideline expansion to CD4 350 Guideline expansion to CD4 500
N sites Median baseline
6-month CI-ART (IQR)
N patients Estimate (95% CI) N sites Median baseline
6-month CI-ART (IQR)
N patients Estimate (95% CI)
Overall 145 53 (46–59) 169,717 4.3 (2.6–6.1) 152 57 (50–64) 128,552 15.9 (14.3–17.4)
Patient level (medians and estimates of change in 6-month CI-ART are restricted to patient strata)
Sexa
Men 129 56 (48–64) 66,656 4.1 (2.2–5.9) 117 61 (52–68) 50,116 13.7 (12.0–15.4)
Women 127 54 (45–58) 101,284 4.6 (2.6–6.5) 131 58 (50–64) 74,154 16.8 (15.0–18.6)
Age at enrollmenta
16–24 years 90 45 (35–51) 28,150 4.4 (2.0–6.8) 82 51 (45–58) 22,210 21.5 (18.9–24.2)
25 years 143 55 (48–62) 139,228 4.4 (2.6–6.1) 148 60 (50–67) 102,974 15.5 (13.8–17.3)
CD4 count at enrollmentb
CD4 201–350 (newly
eligible)
91 61 (50–70) 29,964 18.2 (15.3–21.1)
CD4 200 (previously
eligible)
91 84 (80–88) 49,615 −0.6 (−2.0–0.7)
CD4 351–500 (newly
eligible)
52 36 (27–45) 10,824 47.4 (41.5–53.4)
CD4 350 (previously
eligible)
52 84 (78–88) 36,199 4.9 (3.3–6.5)
Site level (medians and estimates of change in 6-month CI-ART are for overall site population)
Region
Asia-Pacific 6 74 (47–76) 2,868 12.0 (-4.2–28.1) 2 73 (62–83) 378 13.5 (-0.5–27.4)
Central Africa 12 37 (31–46) 5,886 7.3 (-3.5–18.1) 13 55 (52–61) 3,559 7.4 (0.4–14.3)
East Africa 36 53 (47–56) 42,804 7.6 (4.3–10.9) 46 53 (47–59) 36,856 15.8 (12.9–18.6)
North America 13 46 (40–55) 7,262 4.6 (-0.2–9.4) 10 50 (43–59) 6,949 13.7 (9.4–18.1)
Southern Africa 73 56 (49–62) 109,012 1.7 (-0.5–3.8) 78 60 (51–66) 79,664 17.6 (15.2–20.0)
South and Central
America
5 54 (52–68) 1,885 4.9 (-4.1–13.7) 3 62 (61–71) 1,146 12.1 (6.5–17.7)
Site setting
Urban 72 52 (41–58) 81,077 5.3 (3.0–7.7) 65 58 (52–62) 60,410 14.2 (12.1–16.3)
Rural 42 56 (50–60) 61,200 4.7 (1.3–8.1) 52 56 (48–66) 45,690 16.7 (14.0–19.4)
Unknown 31 52 (42–62) 27,440 1.4 (-2.4–5.3) 35 61 (50–65) 22,452 17.7 (12.7–22.7)
% female (overall, in “pre” and “post” periods)
45% 24 53 (41–63) 12,006 6.5 (1.4–11.6) 17 60 (46–62) 9,142 14.7 (11.4–18.1)
>45–65% 75 53 (46–60) 109,189 3.8 (1.4–6.2) 88 60 (49–66) 92,559 17.1 (14.9–19.4)
>65% 46 54 (45–58) 48,522 4.4 (1.5–7.2) 47 53 (50–59) 26,851 13.8 (11.0–16.5)
Baseline (“pre” period) 6-month CI-ART among all patients
Top quartile 37 66 (62–71) 56,226 0.4 (−2.2–2.9) 38 69 (66–74) 48,519 10.6 (8.6–12.7)
Middle-high quartile 36 56 (54–58) 53,729 3.0 (−0.1–6.0) 38 61 (59–62) 35,632 16.8 (14.4–19.2)
Middle-low quartile 35 50 (47–52) 30,726 3.0 (−0.2–6.1) 38 53 (52–55) 26,486 12.4 (9.6–15.1)
Bottom quartile 37 37 (32–41) 29,036 11.8 (7.4–16.2) 38 42 (38–47) 17,915 26.2 (20.7–31.7)
Baseline (“pre” period) 6-month CI-ART among previously ART eligible patientsc
Top quartile 32 57 (48–67) 21,874 −0.1 (−3.5–3.4) 32 63 (60–69) 23,656 12.9 (10.2–15.7)
Middle-high quartile 32 56 (52–62) 35,844 3.7 (−0.1–7.5) 33 63 (58–68) 38,794 14.4 (12.0–16.9)
Middle-low quartile 32 55 (49–60) 60,833 5.9 (2.2–9.7) 31 57 (51–62) 35,175 16.2 (12.8–19.7)
Bottom quartile 32 51 (40–55) 48,158 5.5 (2.8–8.2) 33 47 (42–52) 26,946 19.3 (13.8–24.7)
“post” period % ART eligible under expanded guidelinesd,e
Top quartile 36 55 (47–60) 45,601 4.9 (2.4–7.5) 37 60 (50–63) 27,394 14.6 (11.2–18.0)
(Continued )
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expansion to CD4 500 cells/μL, appreciably larger increases were observed among women
when compared to men (16.8 versus 13.7 pp) and among patients aged 16–24 years at enroll-
ment, compared to those 25 years or older (21.5 versus 15.5 pp). Striking differences were also
observed in pooled estimates of change in CI-ART by CD4 count at enrollment. Specifically,
while no or minimal improvement was observed among patients who were already ART eligi-
ble before guideline expansion, a large increase was noted among those newly eligible for treat-
ment under the expanded ART criteria (18.2 pp among newly eligible patients after expansion
to CD4 350 cells/μL and 47.4 pp among newly eligible patients after expansion to
CD4 500 cells/μL; Table 2, Fig 2).
Metaregression: Predicted and adjusted effects
Six-month CI-ART during the period before ART eligibility expansion was the strongest corre-
late of change in CI-ART following eligibility expansion. In bivariate analyses, the predicted
change in 6-month CI-ART after expansion to CD4 350 was 9.1 pp for a site with “pre”-period
CI-ART of 40% and 1.4 pp for a site with “pre”-period CI-ART of 60%. After expansion to
CD4 500, the predicted changes in CI-ART were 24.1 pp and 14.6 pp, respectively. In adjusted
metaregression models, “pre”-period 6-month CI-ART was the strongest correlate of pp change
in 6-month CI-ART after ART eligibility expansion (Table 3). Adjusted changes in CI-ART fol-
lowing both ART eligibility expansions were greatest among those sites with lower pre-expansion
levels of CI-ART; each 10-unit decrease in the “pre”-period 6-month CI-ART was associated
with an average 3.9 and 5.3 pp change in CI-ART after CD4 350 and CD4 500 cells/μL eligi-
bility expansions, respectively. Increasing cohort size was also positively associated with change
in CI-ART (Table 3).
Metaregression models adjusting for site, patient population, and guideline characteristics
explained 24.1% and 38.1% of between-site variability, with tau-squared reduced from 126.1 to
95.7 and from 110.4 to 68.3 in the CD4 350 and CD4 500 analyses, respectively.
Discussion
Our study found that expansions in ART eligibility criteria for people with HIV infection were
followed by substantial increases in rates of timely ART initiation at the original clinic of
enrollment, with much larger increases among those newly eligible under the expanded guide-
lines compared with those eligible under prior guidelines. Importantly, with expansion to
CD4 500, increases were most pronounced for persons aged 16–24 years, a critical popula-
tion that has historically been particularly difficult to engage in care. For both ART eligibility
Table 2. (Continued)
Guideline expansion to CD4 350 Guideline expansion to CD4 500
N sites Median baseline
6-month CI-ART (IQR)
N patients Estimate (95% CI) N sites Median baseline
6-month CI-ART (IQR)
N patients Estimate (95% CI)
Middle-high quartile 36 55 (45–58) 53,044 7.9 (4.4–11.4) 37 57 (49–63) 32,586 16.9 (13.9–20.0)
Middle-low quartile 36 55 (49–61) 37,526 2.6 (−0.2–5.5) 37 59 (52–65) 37,936 16.0 (13.0–19.0)
Bottom quartile 37 47 (39–54) 33,546 1.4 (−3.2–5.9) 37 55 (48–62) 29,114 16.2 (11.7–20.8)
a Includes only sites with30 patients in each “pre” and “post” period in the given stratum
b Includes only sites with30 patients in each “pre” and “post” period in both strata
c Includes only sites with30 previously eligible patients in the “pre” period
d Includes only sites with10 patients with known ART eligibility in the “post” period
e Patients with unknown eligibility included in denominator of proportions.
https://doi.org/10.1371/journal.pmed.1002534.t002
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Fig 1. Site-level changes in 6-month cumulative incidence of antiretroviral treatment initiation (CI-ART) after guideline expansions to (A)
CD4 350 and (B) CD4 500. Pooled estimates and confidence intervals are in gray.
https://doi.org/10.1371/journal.pmed.1002534.g001
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expansions examined (i.e., to CD4 350 and CD4 500), changes in 6-month CI-ART were
greatest at sites that had lower rates of ART initiation prior to ART eligibility expansion and,
in metaregression analyses, “pre”-period rates of ART initiation were significantly and
Fig 2. Distribution of site-level changes in 6-month cumulative incidence of antiretroviral treatment initiation (CI-ART)
after expansions to CD4 350 and CD4 500, by patient ART eligibility status at enrollment. a Defined as those enrolling
at CD4 200 (in the expansion to CD4 350 analysis) and those enrolling at CD4 between 201 and 350 (in the expansion to
CD4 500 analysis). b Defined as those enrolling at CD4 350 (in the expansion to CD4 350 analysis) and those enrolling
at CD4 between 351 and 500 (in the expansion to CD4 500 analysis).
https://doi.org/10.1371/journal.pmed.1002534.g002
Table 3. Crude and adjusted metaregression analyses of change in 6-month cumulative incidence of antiretroviral treatment initiation (CI-ART) after ART eligibil-
ity guideline expansion to CD4 350 and CD4 500.
Guideline expansion to CD4 350a Guideline expansion to CD4 500a
Site characteristic Unit
Crude
Beta (95% CI)
Adjusteda
Beta (95% CI)
Crude
Beta (95% CI)
Adjusteda
Beta (95% CI)
Baseline 6-month CI-ART 10 pp decrease 3.8 (2.3–5.3) 3.9 (2.4–5.4) 4.8 (3.4–6.1) 5.3 (3.9–6.7)
Baseline median CD4 at enrollment 10 cell/μl increase 0.4 (0.2–0.7) 0.0 (−0.3–0.3)
Median age at enrollment 1-year increase −0.5 (−1.1–0.2) 0.0 (−0.6–0.6)
Proportion female 1-pp increase −0.1 (−0.2–0.1) 0.0 (−0.1–0.1)
Cohort size 1-log increase 1.0 (−1.0–3.0) 2.6 (0.8–4.5) 0.0 (−1.9–1.9) 2.0 (0.3–3.7)
Setting Urban 0.6 (−4.0–5.3) −2.7 (−7.0–1.6)
Rural Reference Reference
Unknown −3.3 (−9.0–2.4) 1.1 (−3.9–6.2)
a The model was also adjusted for ART eligibility concurrently expanded to encompass all individuals with tuberculosis or pregnancy.
https://doi.org/10.1371/journal.pmed.1002534.t003
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inversely associated with changes in CI-ART following guideline change. Larger increases in
CI-ART overall were observed following the adoption of CD4 count500 cells/μL treatment
eligibility guidelines, with statistically significant increases in CI-ART observed at 74% of sites
and a dramatic shift in the pooled estimate of CI-ART across all sites included in the analysis.
Concern has been expressed that expanding ART eligibility may result in sick patients
being “crowded out” by asymptomatic patients [32]. Importantly, and consistent with research
from South Africa [33,34], increases in ART initiation among newly eligible patients on aver-
age were not offset by decreases in ART initiation rates among previously eligible patients,
meaning that access to treatment by sicker patients with lower CD4 counts did not decrease
when patients with higher CD4 counts became eligible and started treatment. In fact, sites
with the lowest baseline ART initiation rates among previously eligible patients saw the great-
est overall increases in ART initiation after guideline expansion, which also suggests that
broadened treatment eligibility did not compromise access for sicker patients.
Another major finding of our study is that increases in timely ART initiation were largest
among young adults—a group that has been consistently shown to have lower rates of reten-
tion in care both prior to and after ART initiation, as well as lower rates of ART initiation at
early stages of infection [35–38]. Improving timely ART initiation among young adults is par-
ticularly important, given that this age group accounts for almost half of new HIV infections
among adults [39].
To our knowledge, no analyses to date have assessed differences in ART initiation following
major changes in HIV treatment eligibility criteria across multiple countries and regions. While
the results of this analysis are promising, further research is needed to assess how increases in
ART initiation at higher CD4 counts and among asymptomatic patients affect retention in the
HIV care continuum over the longer term, including ART adherence, and sustained HIV viro-
logic suppression. While some studies have suggested increased loss to follow-up on ART
among patients with higher CD4 counts [40,41], evidence increasingly supports improved re-
tention among patients initiating with higher CD4 counts [15], including those immediately eli-
gible for ART versus those just under the eligibility threshold [20], and same-day (or “rapid”)
ART initiators [42], with any increases in loss to follow-up more than offset by eliminating
opportunity for pre-ART attrition [43].
The results of this study are important, given a recent systematic review of national HIV
treatment cascades, which indicated that the most common “break point” in the HIV care cas-
cade is between diagnosis and initiation of ART [10], which is critical for achieving optimal
HIV care outcomes at the individual and population level [44]. In conjunction with efforts to
improve HIV testing and linkage to care [45,46], in part via point-of-care CD4 testing to assess
patients’ ART eligibility [47], accelerating the adoption of expanded treatment eligibility crite-
ria, including WHO’s current “Treat All” recommendation, could help reduce rates of pre-ART
loss to clinic and increase rates of timely ART initiation. Mathematical models suggest that
improving rates of HIV testing, linkage, and immediate ART initiation, combined with other
prevention interventions, could nearly stop HIV transmission [48].
At the country level, however, treatment guidelines often lag behind WHO guidance, creat-
ing missed opportunities to realize the preventive potential of ART [26,27]. A recent analysis
of HIV treatment policy changes in sub-Saharan Africa found that the average time for the
adoption of the 2013 guidelines was 10 months (range 0 to 36 months) [26]. Compounding
delays in the national adoption of global guidance are lags in the practical implementation of
new treatment policies at the service delivery level, where outdated practices among frontline
health workers, treatment readiness requirements, and resource constraints lead to further
delays in ART initiation among eligible HIV patients [49]. Confirming the importance of ser-
vice delivery factors in promoting more timely ART initiation, a large intervention study in
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Uganda recently demonstrated a substantial increase in the proportion of eligible patients ini-
tiating ART within 14 days of eligibility determination from 38% to 80% (a 42 pp increase)
through relatively simple and low-cost changes at the health facility level [50]. Our study
results highlight the importance of promoting ART eligibility expansions, including universal
test-and-treat guideline scenarios, with complementary strategies at the facility level to maxi-
mize timely diagnosis and ART initiation rates among ART-eligible persons.
Major strengths of this study include the analysis of data from a large number of patients
and sites across several world regions. Patient- and site-level characteristics were used to pro-
vide setting-specific estimates and to adjust for some differences in patient mix across sites.
Where known, concurrent expansions of ART eligibility criteria regarding pregnancy and
tuberculosis status were also controlled for, to account for varied scopes and foci of guideline
changes. Findings from this large and heterogeneous sample of real-world service delivery set-
tings may be generalizable to many contexts, especially where substantial room remains to
expand ART eligibility guidelines. Additionally, the use of a 12-month buffer period around
the national guideline change date helped both to reduce exposure misclassification and to
control for differences in patient mix and seasonal patterns of ART initiation in within-site
pre-post comparisons.
However, even with the use of a buffer period, the lack of data on the exact timing of site-level
implementation of expanded ART eligibility guidelines likely contributed to imprecision of the
site-level CI-ART estimates, as implementation of expanded guidelines may have preceded
national adoption at some sites and lagged at other sites. Furthermore, the inclusion of 171 sites
from 22 countries necessarily means considerable heterogeneity of ART referral and record-keep-
ing practices, which may have also affected the precision of the estimates. With half of all sites
and over 60% of patients in this analysis being from Southern Africa, overall estimates are str-
ongly influenced by this region. However, changes in CI-ART were similar across regions, espe-
cially in the expansion to CD4500 analysis, albeit with some regions having lower volumes of
data (Asia-Pacific and South and Central America) and therefore less precise CI-ART estimates.
While many sites experienced increases in timely ART initiation, particularly after treat-
ment eligibility was expanded to CD4 500 cells/μL, no change in CI-ART and occasional
decreases in CI-ART were also observed, possibly as a result of unmeasured site-level factors
(e.g., medication or reagent shortages, staffing changes, and other resource constraints). We
did not have data on many facility- and patient population-related factors that could help illu-
minate the reasons behind observed decreases in ART initiation at selected sites after country-
level guideline expansion. In addition, random fluctuation or regression to the mean may help
explain some decreases and increases (for example, changes observed among sites with lowest
“pre”-period ART initiation rates).
Nuanced expansions in national ART eligibility criteria related to clinical stage and preg-
nancy and tuberculosis status, as well as special populations, such as sex workers and serodis-
cordant couples, could not be reflected in this analysis. Furthermore, assumptions of a
midyear policy change for countries where the exact month of ART eligibility expansion was
unknown, in combination with possible early or delayed site-level implementation of national
guidelines, may have obscured the effects of guideline change at the site level.
The increases in CI-ART that we observed may also overestimate the true impact of ART eli-
gibility expansions, given our inability to directly account for secular trends in CI-ART and lack
of a counterfactual within countries during the periods bracketing ART eligibility expansions.
However, the change in timely ART initiation among those previously eligible after the guide-
line expansion is likely a good proxy for what would have happened to those newly eligible
under the guideline expansion had the guideline not changed. The larger increase in timely
ART initiation among those newly eligible (18.2 pp for CD4 350 and 47.4 pp for CD4 500)
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versus those previously eligible (no change for CD4 350 and a small increase of 4.9 pp for
CD4 500) is more consistent with a guideline effect than a secular trend.
While our study design precludes causal attribution, recent research in South Africa,
including studies that used regression discontinuity analysis to account for secular trends
prior to and following eligibility expansions [33,45], as well as to examine ART initiation rates
just above and just under eligibility threshold [20], lend support for a causal association
between ART eligibility expansions and increases in ART initiation.
Conclusions
Our study of a global sample of HIV clinics indicates that ART eligibility expansion was fol-
lowed by substantial increases in timely ART initiation at the original site of enrollment,
including among young adults aged 16–24 years, as well as at clinics with lower rates of timely
ART initiation prior to treatment eligibility expansions. That many clinics can support the ini-
tiation of ART among newly eligible patients with less advanced disease without an adverse
impact on ART initiation rates among those with more advanced disease may reflect a transi-
tion away from the emergency treatment era in some locations. While we did not have suffi-
cient data available to assess the changes in CI-ART following the implementation of the
currently recommended Treat All approach, these findings underscore the utility of ART eligi-
bility expansion as an essential strategy in support of the UNAIDS 90-90-90 targets globally.
As countries increasingly adopt WHO’s Treat All recommendation, future research should
explore its impact on timely ART initiation, as well as other longer-term HIV care outcomes,
including retention, ART adherence, and sustained virologic suppression.
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